[Cognition disorders in the course of treatment with neuroleptics].
D000293:Adolescent; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001921:Brain / Q000187:drug effects; D002746:Chlorpromazine / Q000009:adverse effects; D002749:Chlorprothixene / Q000009:adverse effects; D003072:Cognition Disorders / Q000139:chemically induced; D005260:Female; D005476:Fluphenazine / Q000009:adverse effects; D006220:Haloperidol / Q000009:adverse effects; D006801:Humans; D008297:Male; D008728:Methotrimeprazine / Q000009:adverse effects; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy; D014149:Tranquilizing Agents / Q000009:adverse effects*
D014150:Antipsychotic Agents; D014149:Tranquilizing Agents; D008728:Methotrimeprazine; D002749:Chlorprothixene; D006220:Haloperidol; D005476:Fluphenazine; D002746:Chlorpromazine
Zaburzenia swiadomości w przebiegu kuracji neuroletpycznych.